Technion researchers push quantum, AI and cancer science forward together

[Cheugy]

A profile from ynet News steps away from the usual corporate quantum and AI headlines to look at what is actually happening inside one of Israel's leading research institutions right now. The piece pulls together three very different frontiers being worked on at the Technion, spanning quantum systems, artificial intelligence and cancer treatment, and frames them as connected examples of the same underlying research culture rather than three unrelated stories bolted together.

On the quantum side, Professor Yoav Sagi's lab works with ultracold atoms to study quantum systems from first principles, the kind of foundational physics work that eventually feeds into the more applied quantum computing research getting funded elsewhere in the industry right now. It is a reminder that behind every commercial quantum announcement sits years of unglamorous lab physics that rarely makes headlines on its own.

The cancer research angle is arguably the most striking part of the piece. Dr Assaf Zinger's team has built nanoparticles embedded with white blood cell membrane proteins that send biological signals telling cancer cells to stop dividing, rather than relying on chemotherapy to kill cells directly. Zinger is refreshingly candid about where the science actually stands, noting bluntly that we can cure cancer in mice, we are not doing that very well in humans yet, which is the kind of honesty that rarely survives into a press release.

On the AI side, Professor Lihi Zelnik-Manor brings three decades of computer vision experience to a question that feels increasingly relevant given how saturated the current AI conversation has become, which is what comes after AI rather than just what AI itself can do. Her framing, what can you do with AI and beyond AI, pushes past the current hype cycle toward asking what the next layer of applied research actually looks like once the current wave of tools becomes ordinary infrastructure.

Zelnik-Manor's closing point about the Technion's role is probably the most quietly important idea in the whole piece. The Technion is not about identifying the breakthrough itself, she argues, it is about building the talent and ecosystem that produces breakthroughs repeatedly over time. That is a very different institutional goal than chasing a single headline result, and it is arguably the harder and more valuable thing to build.

Beyond the breakthrough: inside the Technion labs shaping the technologies of tomorrowwww.ynetnews.com

[Transformer Elk]

Zinger's line about curing cancer in mice but not in humans yet should be printed on the wall of every biotech press office. So much cancer research coverage skips straight past that gap and it is the single biggest reason so many promising therapies never make it to actual patients.